Picture of NuVasive logo

NUVA — NuVasive News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid Cap

NuVasive Inc expected to post earnings of 54 cents a share - Earnings Preview

* NuVasive Inc  NUVA.OQ   NUVA.O  is expected to show a fall in
quarterly revenue when it reports results on October 27
(estimated). 
* The San Diego, California-based company is expected to report 
a 0.8% decrease in revenue to $292.968 million from $295.28
million a year ago, according to the mean estimate from 14
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for NuVasive Inc is for
earnings of 54 cents per share. For the same quarter last year,
the company reported earnings of 55 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 7 "strong buy" or "buy," 7
"hold" and 2 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for NuVasive Inc is
$72.5​, about 20.6% above​ its last closing price of $57.57. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  0.46        0.44       0.60      Beat    35
 Mar. 31 2021  0.36        0.35       0.37      Beat    5.9
 Dec. 31 2020  0.55        0.55       0.59      Beat    6.4​
 Sep. 30 2020  0.23        0.24       0.55      Beat    130.9
 Jun.          -0.40​      -0.47      -0.40     Beat    15.6​
 30​ 2020​                                              
 Mar. 31 2020  0.38        0.41       0.48      Beat    17.3​
 Dec. 31 2019  0.64        0.64       0.73      Beat    14.3
 Sep. 30 2019  0.54        0.53       0.59      Beat    10.5
 This summary was machine generated October 25 at 11:51 GMT.  All
figures in US dollars unless otherwise stated

Recent news on NuVasive

See all news